Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2003

View Archived Issues

Gabapentin combined with valaciclovir reduces severity and duration of postherpetic neuralgia

MBI-594AN solution safe and effective for reducing acne lesions

Long-lasting antitumor activity reported for Bexxar in refractory B-cell lymphoma

Combination therapy containing zosuquidar reverses multidrug resistance in AML

New data on subantimicrobial doses of Periostat discussed in San Antonio

New PARP inhibitors prepared and tested at Guilford

Pharma Mar identifies new antitumor ecteinascidin derivatives

Novel series of sPLA2 inhibitors described in Lilly patent

Takeda claims new CCR5 antagonists for HIV infection and other uses

Actelion scientists present novel series of endothelin antagonists

Benzopyran beta3-adrenoceptor agonists in Glenmark development pipeline

NeuroSearch describes novel inhibitors of CNS monoamine uptake

Potent alpha-adrenoceptor antagonists with utility in sexual dysfunction

Novel GnRH antagonists discovered by Neurocrine scientists

Lilly advances LY-818 into phase II

GL-48656 preclinical data reported

Galen's Femring approved by U.S. FDA

Incyte Genomics completes acquisition of Maxia

Vernalis reviews 2002 developments

Chronic antagonism of the CB1 receptor results in antiobesity effects in mice

Albaconazole, a broad-spectrum antifungal agent with a favorable overall profile

Methods of prophylaxis and treatment of HER-2/neu tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.